Physio-Control signs consent decree with FDA on QA issues:
This article was originally published in Clinica
Physio-Control, a Medtronic subsidiary and developer of external defibrillators, has agreed with the US FDA on a plan that would resolve quality issues at its Redmond, Washington facility and enable the company to resume US distribution of its products. Medtronic suspended US shipments of the defibrillators from the plant in January 2007 (see Clinica No 1241, p 13). According to Brian Webster, president of Physio-Control, the Minneapolis, Minnesota-based firm has made "significant investments and improvements" to its technology over the last year. Meanwhile, shipments of the products to non-US customers will continue as normal.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.